Using Neuropharmaceuticals for Cognitive Enhancement: Policy and Regulatory Issues

  • Jayne LuckeEmail author
  • Brad Partridge
  • Cynthia Forlini
  • Eric Racine
Reference work entry


This chapter provides an overview of policy and regulatory issues relating to the use of neuropharmaceuticals for cognitive enhancement in normal persons without a cognitive disorder. It draws on experience with a range of policy and regulatory approaches to alcohol, tobacco, pharmaceutical drugs, and illicit drugs and focuses on approaches that target rates of drug use in the population as a whole. The focus on regulatory interventions for the control of neuropharmaceuticals is important because a range of pharmaceutical drugs is often reportedly used and advocated for enhancement purposes. We also examine how more public health interventions such as awareness raising, education, and stigmatization could be used as preventive strategies to reduce the use, and harm associated with the use, of neuropharmaceuticals for cognitive enhancement.


Illicit Drug Public Health Intervention Regulatory Approach Cognitive Enhancement Pharmaceutical Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Academy of Medical Sciences. (2008). Brain science, addiction and drugs. London: United Kingdom Academy of Medical Sciences.Google Scholar
  2. Australian Press Council. (2001). Guideline: Drugs and drug addiction, Advisory Guidelines. Accessed 5 Nov 2012.
  3. Babor, T., Caulkins, J., Edwards, G., Fischer, B., Foxcroft, D., Humphreys, K., & Strang, J. (2010). Drug policy and the public good. Oxford: Oxford University Press.Google Scholar
  4. Bell, S. K., Lucke, J. C., & Hall, W. D. (2012). Lessons for enhancement from the history of cocaine and amphetamine use. AJOB Neuroscience, 3(2), 24–29.CrossRefGoogle Scholar
  5. Bostrom, N., & Sandberg, A. (2009). Cognitive enhancement: Methods, ethics, regulatory challenges. Science and Engineering Ethics, 15(3), 311–341.CrossRefGoogle Scholar
  6. British Medical Association. (2007). Boosting your brainpower: Ethical aspects of cognitive enhancements. London: BMA.Google Scholar
  7. Carroll, B. C., McLaughlin, T. J., & Blake, D. R. (2006). Patterns and knowledge of nonmedical use of stimulants among college students. Archives of Pediatrics & Adolescent Medicine, 160(5), 481–485.CrossRefGoogle Scholar
  8. DeSantis, A., Webb, E. M., & Noar, S. M. (2008). Illicit use of prescription ADHD medications on a college campus: A multimethodological approach. Journal of American College Health, 57(3), 315–324.CrossRefGoogle Scholar
  9. Dubljevic, V. (2012). Toward a legitimate public policy on cognition-enhancement drugs. AJOB Neuroscience, 3(3), 29–33.CrossRefGoogle Scholar
  10. Fischer, B., Bibby, M., & Bouchard, M. (2010). The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in North America: A review of sourcing routes and control measures. Addiction, 105(12), 2062–2070.CrossRefGoogle Scholar
  11. Forlini, C., & Racine, E. (2009). Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: Perspectives of key stakeholders. Neuroethics, 2(3), 163–177.CrossRefGoogle Scholar
  12. Forlini, C., & Racine, E. (2012). Added stakeholders, added value(s) to the cognitive enhancement debate: Are academic discourse and professional policies sidestepping values of stakeholders? AJOB Primary Research, 3(1), 33–47.CrossRefGoogle Scholar
  13. Forlini, C., Gauthier, S., & Racine, E. (2013). Should physicians prescribe cognitive enhancers to healthy individuals? Canadian Medical Association Journal. Online ahead of print: 10.1503/cmaj.121508.Google Scholar
  14. Franke, A. G., Bonertz, C., Christmann, M., Huss, M., Fellgiebel, A., Hildt, E., & Lieb, K. (2011). Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry, 44(2), 60–66.CrossRefGoogle Scholar
  15. Fraser, S., & Moore, D. (2011). Governing through problems: The formulation of policy on amphetamine-type stimulants (ATS) in Australia. The International Journal on Drug Policy, 22(6), 498–506.CrossRefGoogle Scholar
  16. Government of Quebec. (2009). Psychotropic drugs and expanded uses: An ethical perspective (Position Statement) Quebec: Commission de l’éthique, de la science et de la technologie.Google Scholar
  17. Greely, H., Sahakian, B., Harris, J., Kessler, R. C., Gazzaniga, M., Campbell, P., & Farah, M. J. (2008). Towards responsible use of cognitive-enhancing drugs by the healthy. Nature, 456(7223), 702–705.CrossRefGoogle Scholar
  18. Hall, W. (2004). Feeling ‘better than well:’ Can our experiences with psychoactive drugs help us to meet the challenges of novel neuroenhancement methods? EMBO Reports, 5(12), 1105–1109.CrossRefGoogle Scholar
  19. Holmes, D. (2012). Prescription drug addiction: The treatment challenge. Lancet, 379(9810), 17–18.CrossRefGoogle Scholar
  20. Hughes, B., & Winstock, A. R. (2012). Controlling new drugs under marketing regulations. Addiction, 107(11), 1894–1899.CrossRefGoogle Scholar
  21. Kroutil, L. A., Van Brunt, D. L., Herman-Stahl, M. A., Heller, D. C., Bray, R. M., & Penne, M. A. (2006). Nonmedical use of prescription stimulants in the United States. Drug and Alcohol Dependence, 84(2), 135–143.CrossRefGoogle Scholar
  22. Larriviere, D., Williams, M. A., Rizzo, M., & Bonnie, R. J. (2009). Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology, 73(17), 1406–1412.CrossRefGoogle Scholar
  23. Lucke, J. C., Bell, S., Partridge, B., & Hall, W. D. (2011). Deflating the neuroenhancement bubble. AJOB Neuroscience, 2(4), 38–43.CrossRefGoogle Scholar
  24. Lynch, G., Palmer, L. C., & Gall, C. M. (2011). The likelihood of cognitive enhancement. Pharmacology, Biochemistry, and Behavior, 99(2), 116–129.CrossRefGoogle Scholar
  25. McCabe, S. E. (2008). Misperceptions of non-medical prescription drug use: A web survey of college students. Addictive Behaviors, 33(5), 713–724.CrossRefGoogle Scholar
  26. Nielsen, S., & Barratt, M. J. (2009). Prescription drug misuse: Is technology friend or foe? Drug and Alcohol Review, 28(1), 81–86.CrossRefGoogle Scholar
  27. Orizio, G., Merla, A., Schulz, P. J., & Gelatti, U. (2011). Quality of online pharmacies and websites selling prescription drugs: A systematic review. Journal of Medical Internet Research, 13(3), e74.CrossRefGoogle Scholar
  28. Outram, S. M., & Racine, E. (2011a). Developing public health approaches to cognitive enhancement: An analysis of current reports. Public Health Ethics, 4(1), 93–105.CrossRefGoogle Scholar
  29. Outram, S. M., & Racine, E. (2011b). Examining reports and policies on cognitive enhancement: Approaches, rationale, and recommendations. Accountability in Research, 18(5), 323–341.Google Scholar
  30. Partridge, B. J., Bell, S. K., Lucke, J. C., Yeates, S., & Hall, W. D. (2011). Smart drugs “as common as coffee”: Media hype about neuroenhancement. PLoS One, 6(11), e28416.CrossRefGoogle Scholar
  31. Racine, E. (2008). Interdisciplinary approaches for a pragmatic neuroethics. The American Journal of Bioethics, 8(1), 52–53.CrossRefGoogle Scholar
  32. Racine, E. (2010). Pragmatic neuroethics: Improving treatment and understanding of the mind-brain. Cambridge, MA: The MIT Press.Google Scholar
  33. Racine, E., & Forlini, C. (2009). Expectations regarding cognitive enhancement create substantial challenges. Journal of Medical Ethics, 35(8), 469–470.CrossRefGoogle Scholar
  34. Racine, E., & Forlini, C. (2010). Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. [Letter]. Neurology, 74(19), 1555–1556.CrossRefGoogle Scholar
  35. Repantis, D., Schlattmann, P., Lainsey, O., & Heuser, I. (2008). Antidepressants for neuroenhancement in healthy individuals: A systematic review. Poiesis Prax, 6, 139–174.CrossRefGoogle Scholar
  36. Repantis, D., Laisney, O., & Heuser, I. (2010a). Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 61(6), 473–481.CrossRefGoogle Scholar
  37. Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010b). Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research, 62(3), 187–206.CrossRefGoogle Scholar
  38. Roche, A. M., Bywood, P., Pidd, K., Freeman, T., & Steenson, T. (2009). Drug testing in Australian schools: Policy implications and considerations of punitive, deterrence and/or prevention measures. The International Journal on Drug Policy, 20(6), 521–528.CrossRefGoogle Scholar
  39. Room, R., & Hall, W. (2012). Population approaches to alcohol, tobacco and drugs: Effectiveness, ethics and interplay with addiction neuroscience. In A. Carter, W. D. Hall, & J. Illes (Eds.), Addiction neuroethics (pp. 247–260). London: Academic Press.CrossRefGoogle Scholar
  40. Rosenfield, D., Hebert, P. C., Stanbrook, M. B., Flegel, K., & MacDonald, N. E. (2011). Time to address stimulant abuse on our campuses. [Editorial]. Canadian Medical Association Journal, 183(12), 1345.CrossRefGoogle Scholar
  41. Sandberg, A., & Savulescu, J. (2011). The social and economic impacts of cognitive enhancement. In J. Savulescu, R. ter Meulen, & G. Kahane (Eds.), Enhancing human capacities. Oxford, UK: Blackwell.Google Scholar
  42. Savulescu, J., & Bostrom, N. (Eds.). (2009). Human enhancement. Oxford: Oxford University Press.Google Scholar
  43. Smith, M. E., & Farah, M. J. (2011). Are prescription stimulants “smart pills”? The epidemiology and cognitive neuroscience of prescription stimulant use by normal healthy individuals. Psychological Bulletin, 137(5), 717–741. 717.CrossRefGoogle Scholar
  44. Stone, A. M., & Merlo, L. J. (2011). Attitudes of college students toward mental illness stigma and the misuse of psychiatric medications. The Journal of Clinical Psychiatry, 72(2), 134–139.CrossRefGoogle Scholar
  45. Strang, J., Babor, T., Caulkins, J., Fischer, B., Foxcroft, D., & Humphreys, K. (2012). Drug policy and the public good: Evidence for effective interventions. The Lancet, 379(9810), 71–83.CrossRefGoogle Scholar
  46. Swanson, J. M., Wigal, T. L., & Volkow, N. D. (2011). Contrast of medical and nonmedical use of stimulant drugs, basis for the distinction, and risk of addiction: Comment on Smith and Farah. [Comment]. Psychological Bulletin, 137(5), 742–748.CrossRefGoogle Scholar
  47. Teter, C. J., McCabe, S. E., LaGrange, K., Cranford, J. A., & Boyd, C. J. (2006). Illicit use of specific prescription stimulants among college students: Prevalence, motives, and routes of administration. Pharmacotherapy, 26(10), 1501–1510.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  • Jayne Lucke
    • 1
    Email author
  • Brad Partridge
    • 1
  • Cynthia Forlini
    • 2
    • 4
  • Eric Racine
    • 3
    • 4
    • 5
  1. 1.University of Queensland Centre for Clinical ResearchThe University of QueenslandBrisbaneAustralia
  2. 2.Institut de recherches cliniques de Montréal (IRCM)Neuroethics Research UnitMontréalCanada
  3. 3.Neuroethics Research Unit, Institut de recherches cliniques de MontréalMontréalCanada
  4. 4.Department of Medicine and Department of Social and Preventive MedicineUniversité de MontréalMontréalCanada
  5. 5.Departments of Neurology and Neurosurgery, Experimental Medicine & Biomedical Ethics UnitMcGill UniversityMontréalCanada

Personalised recommendations